Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

ClearPoint Neuro Q3 revenue misses estimates

By Reuters News


Overview

  • US neuro device maker's Q3 revenue rose 36% yr/yr, driven by IRRAflow and biologics growth

  • Gross margin fell to 58% from 63% due to new lab overhead and amortization costs

  • Company raised $22 mln from equity offering, ending Q3 with $46.2 mln in cash


Outlook

  • Company now estimates 2026 revenue to be between $48.0 mln and $50.0 mln


Result Drivers

  • IRRAFLOW ACQUISITION - Revenue growth in neurosurgery navigation and therapy was primarily driven by additional sales from the acquired IRRAflow product

  • CAPITAL EQUIPMENT SALES - Record capital equipment and software revenue reflected increased placements of navigation, IRRAflow control units, and Prism laser units

  • LAB SERVICES DEMAND - Biologics and drug delivery revenue rose mainly due to higher revenue from services performed at ClearPoint Advanced Laboratories


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Miss

$12.1 mln

$12.30 mln (2 Analysts)

Q3 Gross Margin

58%

Q3 Operating Expenses

$13.4 mln


Analyst Coverage

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

  • Wall Street's median 12-month price target for Clearpoint Neuro Inc is $23.50, about 142.5% above its October 27 closing price of $9.69


Reuters Recommended Reads

  • Oct 28 - Boston Scientific Q3 revenue beats estimates despite cybersecurity disruption

  • Oct 28 - GE Healthcare Q3 profit beats estimates on advanced imaging segment

  • Oct 28 - AxoGen Q3 revenue beats estimates on market expansion


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.